Eli Lilly and Company

Matthew Dale Hilton

Paul R Atkinson

Peter K Lambooy

Cathleen Alice Cantwell

Andrew Richard Cockshott

Penelope Jane Beverly Millar

Brian Gerald Getman

Robert Joseph Strobel, Jr

Dennis Nelson Thomas

Jack Richard Eastridge

A method for producing one or more pseudomycins is described including cultures ofthat produce one or more pseudomycins having general formula (I) where R is a lipophilic moiety. 

Pseudomycin production by pseudomonas syringae

The present invention is directed to a family of unique antimycotic lipopeptide compounds produced by. The lipopeptides are effective against both human and plant fungal pathogens, and are typically characterized by their ability to inhibit growth of. Representative lipopeptides of the invention have molecular weights of 1137, 1153, 1164 and 1181 daltons.

Pseudomycin production by Pseudomonas syringae

A dipeptidylaminopeptidase (dDAP enzyme) and a method for isolating it from the culture medium of the cellular slime mold, Dictyostelium discoideum have been presented. The isolated dDAP enzyme has a pH optimum of about 3.5 and a mass of about 225 kDA. The dDAP enzyme has an activity which is somewhat similar to both DAP-I and DAP-III from this organism. Methods for using the dDAP enzyme to remove dipeptides from the N-terminus of recombinantly produced precursor proteins or peptides are also presented.

Dictyostelium dipeptidylaminopeptidase

A method for removing dipeptides from the amino terminus of precursor polypeptides to produce a polypeptide product is presented which comprises contacting the precursor polypeptide for sufficient time to remove the dipeptide with a dipeptidylaminopeptidase (dDAP) from the slime mold, Dictyostelium descoideum, which has a mass of about 225 kilodaltons and a pH optimum of about 3.5. The precursor polypeptides may be made recombinantly and may be analogs of naturally occurring polypeptides.

Growing community of inventors

Indianapolis, IN, United States of America

Matthew Dale Hilton